Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPOX-T in HER2+ Metastatic Breast Cancer
NCT00216073Phase 2
Key facts
- Status
- Terminated
- Start
- Mar 2004
- Primary completion
- Oct 2006
- Countries
- 1
- Sponsor
- Hoosier Cancer Research Network
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Conditions
- HER2-positive metastatic breast cancer
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, oxaliplatin and trastuzumab in HER2-positive metastatic breast cancer, sponsored by Hoosier Cancer Research Network. Primary endpoint: Objective Response Rate at 18 months. Started Mar 2004; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
CAPOX-T
Capecitabine + Oxaliplatin + Trastuzumab
03
Endpoints
Primary
Objective Response Rate
Secondary
Time to Progression
Clinical Benefit Response
Toxicity Rate
HER2 Extracellular Domain Correlation
Beyond the preview
Go deeper on NCT00216073.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00216073.